EMUC25 special: Dr. Rescigno talks about single agent TKI in selected mRCC patients
About this episode
UROONCO RCC associate editor Assoc. Prof. Carlotta Palumbo (IT) talks with medical oncologist Dr. Pasquale Rescigno (GB) about his presentation supporting the 'yes' position in the debate at EMUC25: “Is single agent TKI (tyrosine kinase inhibitor) still an option in selected mRCC patients?
This interview was recorded at EMUC25 in Prague. For more updates on kidney cancer, please visit our educational platform UROONCO RCC.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.
Get every episode summarized
Each time EAU Podcasts publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from EAU Podcasts
EAUN edition - No place to go: Homelessness & Incontinence
EAU Podcasts
EAU Section of Genitourinary Reconstructive Surgeons: Management of short bulbar...
EAU Podcasts
History Office: Ongoing discoveries from the life of Joaquín Albarrán (1860-1912...
EAU Podcasts
PEACE 2 results: Evaluating pelvic RT for very high-risk PCa
EAU Podcasts